Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Corbilta   
Auth. number : EU/1/13/859
Active substance : levodopa / carbidopa / entacapone
ATC: Anatomical main group: N - Nervous system
Therapeutic subgroup: N04 - Anti-parkinson drugs
Pharmacological subgroup: N04B - Dopaminergic agents
Chemical subgroup: N04BA - Dopa and dopa derivatives
Chemical substance: N04BA03 - levodopa, decarboxylase inhibitor and comt inhibitor
(See WHO ATC Index)
Indication: Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Marketing Authorisation Holder: Orion Corporation
Orionintie 1, 02200 Espoo, Suomi
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/11/2013 Centralised - Authorisation EMEA/H/C/2785 (2013)7953 of 11/11/2013
02/10/2014 Centralised - Variation EMEA/H/C/2785/IA/4
Updated with Decision(2015)7278 of 16/10/2015
22/01/2015 Centralised - Variation EMEA/H/C/2785/WS/665
Updated with Decision(2015)7278 of 16/10/2015
03/06/2015 Centralised - Variation EMEA/H/C/2785/N/6
Updated with Decision(2015)7278 of 16/10/2015
20/10/2015 Centralised - Yearly update (2015)7278 of 16/10/2015
08/02/2018 Centralised - Variation EMEA/H/C/2785/WS/1327